Ketoconazole in the treatment of fungal infection. Clinical and laboratory studies.
Ketoconazole is an effective treatment for chronic superficial candidiasis as well as chronic dermatophytosis. In the latter group of infections the best results were obtained in patients with tinea corporis who were not responsive to griseofulvin. It is possible to maintain some patients with chronic mucocutaneous candidiasis in remission without using prophylactic ketoconazole, although relapses may occur. However, the responses of patients with Hendersonula and Scytalidium infections as well as those with subcutaneous mycoses, such as eumycetoma, were disappointing. Patients who have an inadequate response to ketoconazole may also have subnormal serum levels of the drug and the value of such estimations in routine management needs further evaluation.
D000293:Adolescent; D000328:Adult; D000935:Antifungal Agents / Q000378:metabolism / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy; D002178:Candidiasis, Chronic Mucocutaneous / Q000188:drug therapy; D003881:Dermatomycoses / Q000188:drug therapy; D005260:Female; D006118:Griseofulvin / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000378:metabolism / Q000627:therapeutic use*; D007654:Ketoconazole; D007700:Kinetics; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D003904:Mitosporic Fungi; D009181:Mycoses / Q000188:drug therapy*; D014009:Onychomycosis / Q000188:drug therapy; D010879:Piperazines / Q000378:metabolism / Q000627:therapeutic use*; D014005:Tinea / Q000188:drug therapy
D000935:Antifungal Agents; D007093:Imidazoles; D010879:Piperazines; D006118:Griseofulvin; D007654:Ketoconazole